Gunnar Morken

Gunnar Morken

Auto-generated profile, based on publicly available information

Gunnar Morken

Department of Mental Health, St Olav University Hospital, Trondheim, Norway

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ECeQTLGen Consortium
eQTLGen Consortium
ESEli A. Stahl
Eli A. Stahl
BCBIOS Consortium
BIOS Consortium
TCthe Bipolar Disorder Working Group of the Psychiatric Genomics Consortium
the Bipolar Disorder Working Group of the Psychiatric Genomics Consortium
GBGerome Breen
Gerome Breen
PSPamela Sklar
Pamela Sklar
Bipolar disorder is a highly heritable psychiatric disorder. We performed a genome-wide association study (GWAS) including 20,352 cases and 31,358 controls of European descent, with follow-up analysis of 822 variants with P < 1 × 10−4 in an additional 9,412 cases and 137,760 controls. Eight of the 19 variants that were genome-wide significant (P < 5 × 10−8) in the discovery GWAS were not genome-wide significant in the combined analysis, consistent with small effect sizes and limited power but also with genetic heterogeneity. In the combined analysis, 30 loci were genome-wide significant, including 20 newly identified loci. The significant loci contain genes encoding ion channels, neurotransmitter transporters and synaptic components. Pathway analysis revealed nine significantly enriched gene sets, including regulation of insulin secretion and endocannabinoid signaling. Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis, whereas bipolar II disorder is more strongly correlated with major depressive disorder. These findings address key clinical questions and provide potential biological mechanisms for bipolar disorder.

1 December 2019 in Cell
Verified
Journal Article
Closed access
PLPhil H. Lee
Phil H. Lee
VAVerneri Anttila
Verneri Anttila
HWHyejung Won
Hyejung Won
YFYen-Chen A. Feng
Yen-Chen A. Feng
JRJacob Rosenthal
Jacob Rosenthal
JSJordan Smoller
Jordan Smoller

18 September 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PGPsychiatric GWAS Consortium Bipolar Disorder Working Group
Psychiatric GWAS Consortium Bipolar Disorder Working Group
PSPamela Sklar
Pamela Sklar
SRStephan Ripke
Stephan Ripke
LSLaura J Scott
Laura J Scott
OAOle A Andreassen
Ole A Andreassen
SPShaun M Purcell
Shaun M Purcell

1 June 2018 in Cell
Verified
Journal Article
Closed access
DRDouglas M. Ruderfer
Douglas M. Ruderfer
SRStephan Ripke
Stephan Ripke
AMAndrew McQuillin
Andrew McQuillin
JBJames Boocock
James Boocock
ESEli A. Stahl
Eli A. Stahl
KKKenneth S. Kendler
Kenneth S. Kendler

1 August 2019 in American Journal of Psychiatry
Verified
Journal Article
Closed access
NMNiamh Mullins
Niamh Mullins
TBTim B. Bigdeli
Tim B. Bigdeli
ABAnders D. Børglum
Anders D. Børglum
Jonathan ColemanJonathan Coleman
Jonathan Coleman
DDDitte Demontis
Ditte Demontis
CLCathryn Lewis
Cathryn Lewis

30 April 2008 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
GMGunnar Morken
Gunnar Morken
JWJan H Widen
Jan H Widen
RGRolf W Grawe
Rolf W Grawe
The aims of this study were to describe outcome with respect to persistent psychotic symptoms, relapse of positive symptoms, hospital admissions, and application of treatment by coercion among patients with recent onset schizophrenia being adherent and non-adherent to anti-psychotic medication. The study included 50 patients with recent onset schizophrenia, schizoaffective or schizophreniform disorders. The patients were clinically stable at study entry and had less than 2 years duration of psychotic symptoms. Good adherence to antipsychotic medication was defined as less than one month without medication. Outcomes for poor and good adherence were compared over a 24-month follow-up period. The Odds Ratio (OR) of having a psychotic relapse was 10.27 and the OR of being admitted to hospital was 4.00 among non-adherent patients. Use of depot-antipsychotics were associated with relapses (OR = 6.44). Non-adherence was associated with relapse, hospital admission and having persistent psychotic symptoms. Interventions to increase adherence are needed. Current Controlled Trials NCT00184509. Key words: Adherence, schizophrenia, antipsychotic medication, admittances, relapse.